|
Price: $64.4900
$-0.12 
-0.186%
|
| Day's High:
| $65.19
| Week Perf:
| -3.14 %
|
| Day's Low: |
$ 64.47 |
30 Day Perf: |
-7.17 % |
| Volume (M): |
2,150 |
52 Wk High: |
$ 74.02 |
| Volume (M$): |
$ 138,641 |
52 Wk Avg: |
$64.22 |
| Open: |
$64.55 |
52 Wk Low: |
$52.07 |
|
|
| Market Capitalization (Millions $) |
39,594 |
| Shares
Outstanding (Millions) |
614 |
| Employees |
12,447 |
| Revenues (TTM) (Millions $) |
19,030 |
| Net Income (TTM) (Millions $) |
4,357 |
| Cash Flow (TTM) (Millions $) |
-466 |
| Capital Exp. (TTM) (Millions $) |
0 |
Aflac Incorporated
AFLAC Incorporated was incorporated in 1973 under the laws of the state of Georgia.
AFLAC Incorporated (the Parent Company) is a general business holding company
and acts as a management company, overseeing the operations of its subsidiaries
by providing management services and making capital available. Its principal business
is supplemental health and life insurance, which is marketed and administered
primarily through its subsidiary, American Family Life Assurance Company of Columbus
(AFLAC). AFLAC operates in the United States (AFLAC U.S.) and as a branch in Japan
(AFLAC Japan).
Most of our insurance policies are individually underwritten and marketed at
worksites through independent agents, with premiums paid by the employee. We
believe AFLAC is the worlds leading writer of individually issued policies
marketed at worksites. We continue to diversify our product offerings in both
Japan and the United States. AFLAC Japan sells cancer plans, care plans, general
medical expense plans, medical/sickness riders to our cancer plan, a living
benefit life plan, and an accident plan. AFLAC U.S. sells cancer plans and various
types of health insurance, including accident and disability, fixed-benefit
dental, personal sickness and hospital indemnity, hospital intensive care, long-term
care, and short-term disability plans. We also offer several life insurance
plans in Japan and the United States.
Competition - Japan
In 1974, AFLAC became the second foreign (non-Japanese) life insurance company
to gain direct access to the Japanese insurance market by obtaining an operating
license. Through 1981, we were the only company in Japan authorized to sell
a cancer life insurance policy. In January 2001, Japans insurance market was
deregulated, and we experienced an increase in the number of companies selling
products that compete with our policies. However, based on our growth of premiums
in force, producing agents and customer accounts, we do not believe that our
market position has been significantly impacted by increased competition as
a result of deregulation. Furthermore, we believe the continued development
and maintenance of operating efficiencies will allow us to offer affordable
products at a better value to consumers.
Competition - U.S.
There are approximately 2,000 life and accident and health insurance companies
operating in the United States. We compete against several insurers on a national
basis plus other insurers regionally. We believe that our policies and premium
rates as well as the commissions paid to our sales agents are competitive with
those offered by other companies providing similar types of insurance. However,
we believe that our U.S. business is distinct from our competitors because of
our product focus, distribution system, and name awareness. For most of the
other companies that sell supplemental insurance, it represents a secondary
business. For us, it is our only business and allows us to focus on exploring
new product opportunities while also enhancing our existing products. By doing
so, we believe we offer the best value in the market.
Company Address: 1932 Wynnton Road Columbus, 31999 GA
Company Phone Number: 323.3431 Stock Exchange / Ticker: NYSE AFL
| AFL is expected to report next financial results on August 01, 2023. |
Next quarterly dividend pay out on June 01, 2023. |
|
|
|
Customers Net Income grew by |
AFL's Customers Net Profit Margin fell to |
4.2 % |
4.14 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
An2 Therapeutics Inc
Investors in An2 Therapeutics Inc have reason to be concerned about the recent financial results of the company, which showed significant losses from January to March 31, 2023. The company reported a loss of $-0.79 per share, a significant increase from the $-0.50 per share loss reported in the previous financial reporting period. This is indicative of a worrying trend for shareholders and should give cause for concern.
Furthermore, the revenue for January to March 31, 2023 remained unchanged at $0.00 million from the previous year, despite expectations of growth and improvement for the company. This lack of revenue growth over time is a red flag for investors, as it suggests that the company is struggling to generate increased interest, sales, and traction in the market it operates in.
|
|
Cno Financial Group Inc
Investors, it's time to take note of the exciting advancements happening at Cno Financial Group Inc in this first quarter of 2023. With an impressive 16.35% return on equity (ROE), they have outperformed their own average of 6.1%. Although the ROE fell slightly due to the decline in net income, it is still noteworthy that 718 companies now rank higher than Cno Financial Group Inc in terms of ROE, compared to the fourth quarter of 2022 when over 1000 companies outranked it.
In terms of earnings, Cno Financial Group Inc experienced a one year shortfall of $-0.01 per share and a significant decline in earnings from $0.93 per share to $0.38 per share. However, with a respectable 19.35% jump in revenue to $1.01 billion this quarter, investors should not be deterred. Sequentially, revenue even grew by 3.328% from $973.60 million, indicating a steady improvement in the company's market position.
It is worth noting that Cno Financial Group Inc operates in the highly competitive Accident and Health Insurance industry which has five companies currently performing better. However, investors should not overlook the impressive comeback the company is making, particularly during these uncertain times as it contends with the COVID-19 pandemic.
|
|
Oscar Health Inc
An ordinary Revenue growth in the fiscal first quarter of 2023, by 51.083 % to $1.47 billion fueled to cut losses to $-0.18 per share, from $-0.36 in similar financial reporting period a year before.
|
|
Bright Health Group Inc
|
|
Clover Health Investments Corp
Clover Health Investments Corp, a company that specializes in Medicare Advantage plans, has recorded a cumulative net loss of $-336 million during the 12 months ending in the first quarter of 2023. This has resulted in a whopping negative return on investment (ROI) of -83.77%. These abysmal numbers when compared to other financial sector companies indicate that Clover Health Investments Corp has failed miserably in ensuring its investors get a return on their investment.
With 480 other companies in the financial sector recording a higher return on investment, it is clear that Clover Health Investments Corp is struggling. Its return on investment, overall ranking has progressed from 4653 in the fourth quarter of 2022 to 2000 for the quarter ending on March 31, 2023. Despite this improvement in the overall ranking, the company still has a long way to go to ensure that its investors get a good return on their investment.
|
| Per Share |
Current |
| Earnings (TTM) |
6.93 $ |
| Revenues (TTM) |
31 $
|
| Cash Flow (TTM) |
- |
| Cash |
329.68 $
|
| Book Value |
32.22 $
|
| Dividend (TTM) |
1.62 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
6.93 $
|
| Revenues (TTM) |
31 $ |
| Cash Flow (TTM) |
- |
| Cash |
329.68 $
|
| Book Value |
32.22 $ |
| Dividend (TTM) |
1.62 $ |
|
|
| |
| Japan Earned premiums |
|
Segment |
|
 |
of total Revenue |
| Japan Net investment |
|
Segment |
|
|
of total Revenue |
| Japan Other income |
|
Segment |
|
|
of total Revenue |
| Total AFLAC Japan |
|
Segment |
|
|
of total Revenue |
| U.S. Investment |
|
Segment |
|
|
of total Revenue |
| U.S. Other income |
|
Segment |
|
|
of total Revenue |
| Total AFLAC U.S. |
|
Segment |
|
|
of total Revenue |
| Other business segments |
|
Segment |
|
|
of total Revenue |
| |
|
|
0.56%